OncLive® On Air

In today’s episode, supported by Shorla Oncology, we had the pleasure of speaking with Kate Gasparini, PharmD, BCOP, BCPPS, about the use of the oral formulation of imatinib (Imkeldi) for pediatric and adult patients with select leukemias and other malignancies. Gasparini is a pediatric oncology clinical pharmacy specialist at Memorial Sloan Kettering Cancer Center in New York, New York. In our exclusive interview, Gasparini discussed her role as a clinical pharmacy specialist in pediatric oncology, emphasizing her work in patient care, medication reviews, and supportive care. She also noted challenges in administering treatments to patients with dysphagia and emphasized the need for liquid formulations of common therapies. She explained the significance of the availability of the liquid formulation of imatinib, sharing its benefits for patients who struggle with swallowing. Gasparini also addressed potential barriers to accessing this medication, such as insurance coverage limitations, as well as the importance of considering the volume and palatability of liquid formulations to avoid adverse effects and ensure treatment adherence.

In our exclusive interview, Dr Morgans detailed the evolving role of AR inhibitors in the mHSPC setting, including the recent expanded approval for darolutamide (Nubeqa) for this population. She discussed treatment considerations for determining whether to give docetaxel along with darolutamide; other factors to remember with AR inhibition; and the need to continue driving consensus across practices in the management of prostate cancer.

In today’s episode, we spoke with Naval Daver, MD, about the evolving role of menin inhibition in acute myeloid leukemia (AML) and emerging data with revumenib (Revuforj) presented across ongoing clinical trials. Dr Daver is a professor in the Department of Leukemia and director of the Leukemia Research Alliance Program at The University of Texas MD Anderson Cancer Center in Houston, Texas.

In today’s episode, we spoke with Paolo Tarantino, MD, about key updates in HER2-positive breast cancer presented at the 2025 ASCO Annual Meeting

In today's episode, we spoke with Jonathan W. Goldman, MD, about the phase 2 LUMINOSITY study (NCT03539536) evaluating telisotuzumab vedotin-tllv (Teliso-V; Emrelis) in patients with c-MET protein–overexpressing, nonsquamous, EGFR wild-type advanced non–small cell lung cancer (NSCLC). Dr Goldman is a professor of medicine in the Division of Hematology/Oncology at UCLA, as well as director of Clinical Trials in Thoracic Oncology, associate director of Early Drug Development, and chair of the University of California Lung Cancer Consortium.

In today’s episode, we sat down for part 2 of our discussion with Elizabeth Mittendorf, MD, PhD, MHCM, the 2026-2027 president-elect of the American Society of Clinical Oncology (ASCO). Dr Mittendorf holds numerous leadership roles, including the Robert and Karen Hale Distinguished Chair in Surgical Oncology and vice chair for research in the Department of Surgery at Brigham and Women's Hospital; co-leader of the Breast Program and director of the Breast Immuno-Oncology Program at the Dana-Farber Brigham Cancer Center; co-leader of the Parker Institute for Cancer Immunotherapy at the Dana-Farber Cancer Institute; and a professor of surgery at Harvard Medical School, all in Boston, Massachusetts. In this discussion, Dr Mittendorf shared how ASCO is strategically preparing to address the long-term implications of proposed federal research funding cuts. She emphasized the significant return on investment generated by sustained NIH support, underscoring its role in fostering scientific innovation and stimulating the broader economy. She also advocated for structural reforms to be developed collaboratively with researchers, institutions, and policymakers to ensure continued progress in oncology is maintained, particularly in underfunded areas, such as prevention research. Dr Mittendorf also previewed her broader vision for ASCO, including expanding global collaboration and advancing equitable access to cancer care. She noted that these efforts will be complemented by continued emphasis on multidisciplinary care delivery and mentorship, which she discussed in more detail in part one of our conversation.

In this discussion, guests Joshua Feinberg, a surgical partner from Maimonides, and Gary Schwartz from Maimonides Medical Center’s Anesthesiology department delve into the future of pain management for breast cancer patients. They tackle the innovative No Pain Act and explore cutting-edge techniques like cryoneurolysis aimed at minimizing opioid reliance. The conversation highlights advances in multimodal analgesia and the urgent need to address the opioid crisis within postoperative care, ultimately striving for better patient outcomes and safety.

Elizabeth Mittendorf, the 2026 president-elect of ASCO and an expert in surgical oncology, shares her vision for advancing cancer care. She highlights the need for multidisciplinary approaches and the integration of artificial intelligence to improve efficiency. Mentorship is a recurring theme, as Mittendorf reflects on her own experiences and emphasizes its importance for early-career professionals. She also discusses strategies for addressing global challenges in cancer treatment and enhancing workforce well-being in oncology.

Rahul A. Sheth, an expert in interventional oncology, Yana Najjar, a leading medical oncologist, and Douglas Johnson, a melanoma research director, dive into cutting-edge melanoma treatments. They discuss the role of oncolytic viruses in overcoming immune checkpoint resistance and share insights from the IGNITE trial. The importance of interdisciplinary collaboration between medical oncologists and interventional radiologists in administering these therapies is highlighted. They also touch on safety, workflow challenges, and the promise of innovative combination therapies for advanced cases.

Drs Park and Malla began by talking through the clinical utility of ctDNA in patients with stage II and III colon cancer. Dr Malla referenced the DYNAMIC (ACTRN12615000381583) and observational BESPOKE CRC (NCT04264702) trials, noting that ctDNA serves as a prognostic biomarker for recurrence and is increasingly used to guide post-surgical surveillance.